AVN ISSUED PATENT/ Drug Dependency -- Stock Picks

[ Show ]

Support VoyForums

[ Shrink ]

VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, 2 ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 12:27:35 04/11/01 Wed
Author: AVN ISSUED PATENT/ Drug Dependency
Subject: AVN ISSUED PATENT/ Drug Dependency

AVN ISSUED PATENT/ Drug Dependency

Tuesday April 10, 10:05 am Eastern Time

Press Release

SOURCE: Avanir Pharmaceuticals

Patent Issued for Avanir Licensed Product to Help Break Dependence On
Habit-Forming Narcotics

SAN DIEGO, April 10 /PRNewswire/ -- Avanir Pharmaceuticals (Amex: AVN - news) announced today that the United States
Patent Office issued U.S. Patent No. 6207674 for the use of a combination of dextromethorphan and an oxidase inhibitor
(known as AVP-923) for the weaning of patients from narcotics and anti-depressants. The patent was issued to the inventor, Dr.
Richard Smith. Avanir has the exclusive worldwide rights to develop and market AVP-923 under a sublicense to granted to
Avanir in August of 2000.

The patents claims, among others, that when dextromethorphan and an oxidase inhibitor were administered orally to patients who
had become dependent on morphine and anti-depressants, the patients were able to initially reduced their dosages of the
narcotics. With additional dosing, the combination allowed patients to terminate all use of morphine and anti-depressants, with
minimum withdrawal or other adverse affects.

``The issuance of this patent extends the utility of AVP-923 and reinforces our initial impression of the product as a platform for
potential treatments in many different therapeutic areas,'' said Gerald J. Yakatan, Ph.D., president and CEO of Avanir
Pharmaceuticals.

The company is currently conducting a Phase II/III trial examining the effect of AVP-923 in the treatment of emotional lability in
Amyotrophic Lateral Sclerosis (ALS) patients and a Phase I dose ranging study for the use of AVP-923 in patients with
neuropathic pain.

Avanir Pharmaceuticals, based in San Diego, is an emerging diversified biopharmaceutical company engaged in research,
development, commercialization, licensing and sales of innovative drug products and antibody generation services. The
company's website is http://www.avanir.com.

The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in
conjunction with the company's Annual Report on Form 10-K and other publicly available information regarding the company.
Copies of such information are available from the company upon request. Such publicly available information sets forth many
risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words
like ``estimate,'' ``anticipate,'' ``believe,'' ``plan'' or ``expect''. Research findings and patent claims are not always supportable by
evidenced obtained from subsequent clinical trials. Final review decisions made by the FDA and other regulatory agencies
concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

SOURCE: Avanir Pharmaceuticals

[ Next Thread | Previous Thread | Next Message | Previous Message ]